How can we facilitate research on the risks and potential benefits of novel psychoactive substances?
EClinicalMedicine June 19, 2026
How can we facilitate research on the risks and potential benefits of novel psychoactive substances?
EClinicalMedicine
ISSN 2589-5370
17 papers in the library · 977 citations · publishing 2020-2026
Papers
Nitrous oxide for late-life depression with inadequate antidepressant response: a randomised controlled trial.
EClinicalMedicine April 2, 2026 Antony Salamé, Samuel Bulteau, Gabriel Robert et al.
Background Late-life depression with inadequate antidepressant response is a pressing clinical issue with limited proven therapies. Nitrous oxide (N 2 O) may offer a new therapeutic avenue with rapid and safe antidepressant effects in late-life depression with inadequate antidepressant response. Methods We conducted a double-blind, randomised, placebo-controlled, single-dose trial (November...
Sleep alterations in substance use disorders: a systematic review and meta-analysis.
EClinicalMedicine 2026 Henrique Nunes Pereira Oliva, Tiago Paiva Prudente, Alisson M Paredes Naveda et al. 5 citations
Sleep disturbances are common in individuals with substance use disorders (SUDs), often persisting beyond initial abstinence and hindering recovery. However, the underlying sleep abnormalities warrant further investigation, particularly given mixed findings regarding specific substances. This systematic review and meta-analysis aimed to identify sleep-related abnormalities associated with...
Efficacy of intranasal esketamine versus rTMS for treatment-resistant depression: analysis of individual participant data from two clinical trials.
EClinicalMedicine December 1, 2025 Tyler S Kaster, Yi Dai, Fidel Vila-Rodriguez et al. 5 citations
Repetitive transcranial magnetic stimulation (rTMS) and intranasal esketamine are effective treatment options for treatment-resistant depression (TRD) that have not been directly compared. We aimed to compare the effectiveness of rTMS, intranasal esketamine, and pharmacotherapy for TRD using data from two randomised clinical trials (RCTs). This secondary analysis of individual patient data...
Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.
EClinicalMedicine December 1, 2025 Nadav Liam Modlin, Victoria Williamson, Guy M. Goodwin et al. 2 citations
Post-traumatic stress disorder (PTSD) is a debilitating condition leading to significant personal and societal burden. Standard treatments frequently demonstrate limited efficacy, leading to persistent symptoms and high dropout rates. Psilocybin has shown promise in treating depression, a condition that is often comorbid with PTSD. We aimed to explore participant experiences of psilocybin...
Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds
EClinicalMedicine September 24, 2025 Megan Hosein, Matthew J Reid, Sarah A. Walser et al. 5 citations
The potential for psilocybin, and other psychedelic drugs, to fulfil a much needed and potentially transformative class of psychiatric treatments has garnered significant attention. Consequently, there has been a great deal of interest and investment in accelerating its development and potential implementation in routine clinical practice. However, the expanding scope of scientific discovery,...
Efficacy of an online mindfulness program (MindOnLine) to reduce fear of recurrence in people living with-and beyond-breast, prostate or colorectal cancer: a randomized controlled trial.
EClinicalMedicine August 1, 2025 Patricia M Livingston, Natalie Winter, Lahiru Russell et al.
Fear of cancer recurrence (FCR) is a prevalent and debilitating condition that effects around 60% of people living with cancer. It is severe, persistent, and imposes a significant financial burden on the healthcare system. Given FCR's profound impact on mental health and quality of life, adopting targeted interventions to mitigate its effects is essential. This study reports on the efficacy of...
Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
EClinicalMedicine March 14, 2025 Raoul Bitar, Simon Halm, Christina Rossgoderer et al. 42 citations
Swiss National Science Foundation under the framework of Neuron Cofund, Swiss Neuromatrix Foundation, and Heffter Young Investigator Fellowship Award.
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
EClinicalMedicine September 23, 2024 David Erritzøe, Tommaso Barba, Kyle T. Greenway et al. 46 citations
The Alexander Mosley Charitable Trust and by the founding partners of Imperial College London's Centre for Psychedelic Research.
Ethnoracial inclusion in clinical trials of psychedelics: a systematic review.
EClinicalMedicine August 1, 2024 Marcus Hughes, Albert Garcia‐romeu 42 citations
Prior data indicate limited ethnoracial diversity in studies testing psychedelic-assisted treatments. Regulatory approval for psychedelic treatments may be imminent given growing evidence for safety and efficacy in a variety of psychiatric conditions. Data on racial and ethnic inclusion rates in clinical psychedelic studies since 2018 have not been systematically reported to date. With the...
Ketamine for the treatment of major depression: a systematic review and meta-analysis
EClinicalMedicine August 1, 2023 Stevan Nikolin, Anthony Rodgers, Andreas Schwaab et al. 166 citations
Background: Intranasal esketamine has received regulatory approvals for the treatment of depression. Recently a large trial of repeated dose racemic ketamine also demonstrated efficacy in severe depression. However, uncertainties remain regarding comparative efficacy, dosage, and the time course of response. Methods: In this systematic review and meta-analysis, we searched Embase, Medline,...
Psychedelic medicine and the clinical application of hallucinogens
EClinicalMedicine February 24, 2023
Although humans have used hallucinogens ritualistically for thousands of years, interest in their clinical use for the treatment of mental illness began in the 1950s, when active compounds were first isolated. Restrictive laws came into place in the 1960–70s limiting their medical use and investigation. Societal stigma further hampered progress and although the legal status of hallucinogens...
Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.
EClinicalMedicine February 1, 2023 Robin von Rotz, Eva M Schindowski, Johannes Jungwirth et al. 345 citations
Psilocybin has been suggested as a novel, rapid-acting treatment for depression. Two consecutive doses have been shown to markedly decrease symptom severity in an open-label setting or when compared to a waiting list group. To date, to our knowledge, no other trial compared a single, moderate dose of psilocybin to a placebo condition. In this double-blind, randomised clinical trial, 52...
Corrigendum to 'Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial'.
EClinicalMedicine February 1, 2023 Robin von Rotz, Eva M Schindowski, Johannes Jungwirth et al. 8 citations correction
We wish to provide a correction of the colour representation of Fig. 2 in order to harmonise the colours representing the Psilocybin and the Placebo condition with the corresponding figure caption and with the colour codes from all other figures across the manuscript. Fig. 2 now depicts the Psilocybin condition in blue and the Placebo condition in yellow. The error occurred as a result of an...
Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series
EClinicalMedicine May 7, 2022 Hewa Artin, Sean Bentley, Eamonn Mehaffey et al. 35 citations
Summary: Background: (S)-ketamine is a glutamatergic drug with potent and rapid acting effects for the treatment of depression. Little is known about the effectiveness of intranasal (S)-ketamine for treating patients with comorbid depression and post-traumatic stress disorder (PTSD). Methods: We performed a retrospective case series analysis of clinical outcomes in 35 Veterans with co-morbid...
Psilocybin-assisted group therapy: A new hope for demoralization
EClinicalMedicine October 1, 2020 Peter S. Hendricks 5 citations
Anderson et al.’s [[1]Anderson B.T. Danforth A. Daroff R. Stauffer C. Ekman E. Agin-Liebes G. et al.Psilocybin-facilitated group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.Eclinical Med. 2020; https://doi.org/10.1016/j.eclinm.2020.100538Summary Full Text Full Text PDF Scopus (74) Google Scholar] open-label pilot study of...
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study
EClinicalMedicine September 24, 2020 B. Anderson, Alicia Danforth, Prof Robert Daroff et al. 271 citations
BACKGROUND: Psilocybin therapy has shown promise as a rapid-acting treatment for depression, anxiety, and demoralization in patients with serious medical illness (e.g., cancer) when paired with individual psychotherapy. This study assessed the safety and feasibility of psilocybin-assisted group therapy for demoralization in older long-term AIDS survivor (OLTAS) men, a population with a high...